Changes to This Summary (01/02/2015)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that because a majority of patients are diagnosed when the tumor is still relatively localized and amenable to surgical removal, approximately 73% of all patients with renal cell cancer survive for 5 years (cited National Cancer Institute as reference 3).
Added text about the Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer, a double-blind, randomized, controlled, cross-over trial with a primary endpoint of patient preference for one drug over another, which compared sunitinib followed by pazopanib with pazopanib followed by sunitinib (cited Escudier et al. as reference 34).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.